Important players in mammalian cells include mitofusin 1 and 2 (MFN1 and MFN2), optic atrophy 1 (OPA1) and dynamin-related protein 1 (DRP1). Several triggers, including oxidative stress and ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for ...

A 12-YEAR-OLD boy has been left blind because he would only eat burgers and doughnuts. The unnamed child who lived in the US ...

Biotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to ameliorate symptoms of ...

The most common of these syndromes include hearing loss or obesity, as well as retinal degeneration and/or optic atrophy, and some not only severely affect the overall quality of life of patients ...

Wolfram syndrome can cause a person to have both diabetes mellitus and diabetes insipidus Another condition in which diabetes mellitus and diabetes insipidus occur in the same person is the Wolfram ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...

Muscular atrophy is the thinning, wasting, or loss of muscle tissue, leading to decreased strength and mass. There are various types of muscle atrophy and different treatments for them.

Naismith et al. state that they preferentially recruited patients with severe optic neuritis (with ≤20/200 vision) and poor recovery (to <20/40 vision).This bias in selecting study participants ...

Oct 2024 - PYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based precision medicines for genetic diseases.

LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024- Appointed Jason Mitchell as chief ...

Science Corporation, a biotech startup launched by a Neuralink cofounder who left the company, claims that's achieved a ...